57P - small cell lung cancer: Retrospective review of an institution

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Small-Cell Lung Cancer
Lung and other Thoracic Tumours
Presenter ANA Silva
Citation Annals of Oncology (2017) 28 (suppl_2): ii17-ii20. 10.1093/annonc/mdx088
Authors A. Silva1, I. Guerreiro2, C. Castro2, M. Brandao2, A. Rodrigues2, C. Oliveira2, I. Pousa2, J. Oliveira2, I. Azevedo2, M. Soares2
  • 1Medical Oncology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 PORTO - Porto/PT
  • 2Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto/PT

Abstract

Background

Small cell lung cancer (SCLC) account for 10 to 15% of lung cancers. Despite the high rate of response to chemotherapy and radiotherapy, it is characterized by a rapid growth and development of widespread metastases.

Methods

Retrospective review of patients with SCLC with diagnosis between January 2013 and December 2016 in our institution - Portuguese Oncology Center, Porto. Descriptive analysis and survival evaluation by Kaplan-Meier method. Evaluation of differences between survival curves by log rank test.

Results

From the 144 patients included, 115 (79.9%) were male and the mean age was 65 years (range 42-87). The majority of patients had an ECOG PS 0-1 at diagnosis (n = 91, 64.1%). History of smoking was present in 115 patients (79.8%). Ki-67 was analyzed in 38 patients (36.4%) and was ≥50% in 30 patients. 108 patients (75%) had metastatic disease at diagnosis, more frequently bone (n = 61, 42.4%) and liver (n = 50, 34.7%) metastasis. Initial treatment had palliative intent in 118 patients (81.9%), and 41 (28.5%) underwent only symptomatic treatment. The most commonly used chemotherapy regimen was the doublet of platinum and etoposide (n = 98, 95.1%). The overall response rate (ORR) was 64%. Median overall survival (OS) was 5.5 months (95% confidence interval (CI) 2.9-7.9). Within patients submitted to radical treatment (n = 26, 18.1%), there was relapse in 15 (57.7%), with a median disease free survival of 10.5 months (95% CI: 9.4-11.7). Within patients submitted to palliative treatment there was progression in 43 (not evaluated in 28), with a median progression free survival of 6.3 months (95% CI: 5.9-6.7). The median OS of the patients without metastatic disease at diagnosis was significantly higher than those with metastatic disease (median 15.9 months, 95% CI: 12.3-19.4 versus 3.1 months (95% CI: 2.1 -4.1, p < 0.001).

Conclusions

The results obtained in our sample are in agreement with the existing literature. The discovery of predictive and predictive biomarkers as well as new forms of treatment is urgently needed.

Clinical trial identification

Legal entity responsible for the study

Instituto Portugues de Oncologia do Porto (Portuguese Oncology Institute of Porto, Portugal)

Funding

Instituto Portugues de Oncologia do Porto (Portuguese Oncology Institute of Porto, Portugal)

Disclosure

All authors have declared no conflicts of interest.